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The formation of inclusion bodies (IBs) constitute a frequent event during the production
of heterologous proteins in bacterial hosts. Although the mechanisms leading to their
formation are not completely understood, empirical data have been exploited trying to
predict the aggregation propensity of specific proteins while a great number of strategies
have been developed to avoid the generation of IBs. However, in many cases, the
formation of such aggregates can be considered an advantage for basic research as
for protein production. In this review, we focus on this positive side of IBs formation
in bacteria. We present a compilation on recent advances on the understanding of IBs
formation and their utilization as a model to understand protein aggregation and to explore
strategies to control this process. We include recent information about their composition
and structure, their use as an attractive approach to produce low cost proteins and other
promising applications in Biomedicine.
Keywords: protein aggregation, bacterial inclusion bodies, protein folding, recombinant protein expression,
conformational disease model, drug delivery systems, nanoparticules
INTRODUCTION
The deciphering of the genetic code and the availability of the
first tools and basic procedures in genetic engineering opened
the way for protein production in bacteria. This apparently easy
goal encountered an unexpected difficulty: the accumulation of
the protein of interest as insoluble form and the generation
of inclusion bodies (IBs). Since then the generation of IBs has
been traditionally considered an obstacle to avoid and difficult
to predict. Notwithstanding in the last decade, IBs have been
observed from a different perspective and their study gained
considerable interest. From this point of view, the formation
of IBs in bacteria is seen as part of a general cellular response
related to the presence in the cell of unfolded proteins and
as a pathway for the control of aggregation. From this per-
spective, IBs constitute a valuable model to better understand
protein aggregation in eukaryotes, and for the search of specific
inhibitors or disaggregation approaches, in relation to relevant
conformational diseases. On the other hand, the production of
proteins as aggregates in IBs opened new interesting perspec-
tives for diverse applications in Biomedicine. They can be an
almost pure source of recombinant protein, and because of their
particular structural and functional characteristics they can be
potentially exploited as naturally immobilized enzymes or as
nanomaterials. In this minireview, we focus on this positive
side of IBs formation in bacteria. We include recent informa-
tion about their composition, formation and structure and their
use as an attractive approach to produce proteins at low cost.
We also review the role of IBs as a model to understand pro-
tein aggregation and to explore strategies to control this process.
Finally we describe some promising applications of bacterial
IBs as systems for controlled drug delivery and nanotechnology
applications.
PROTEIN AGGREGATION AS A CONSERVED CELLULAR
RESPONSE
Diverse conditions can lead to an alteration of protein home-
ostasis and to protein aggregation in all living cells. Among
others, the presence of unfolded proteins is increased after a heat
shock or other environmental stress conditions. Some mutations
can lead to the synthesis of unstable protein structures, as well.
Another current event is provided by fast and high expression
of recombinant proteins in bacteria, leading to the formation of
IBs. Recent evidence indicates that in the cell, the quality control
system—regulating chaperones and proteases levels—and protein
aggregation and disaggregation are part of a cellular response to
altered protein homeostasis. In a recent review Tyedmers et al.
(2010) described protein aggregation as a regulated process in
bacteria, yeast and mammalian cells. Interestingly, despite differ-
ences, similarities of protein aggregation in these cells reflect the
universality of the response. In particular, the subcellular localiza-
tion of aggregates is not random but well-defined in each cellular
type. The IBs in bacteria are mainly localized in the cell poles, and
also in septation sites, whereas in yeast protein deposits are close
to vacuoles or to the nucleus. In mammals deposits in aggresomes
are associated to the nucleolus. Another relevant observation is
the similarity at the level of protein structure between bacterial
IBs and the amyloid aggregates characteristic of several human
diseases, the so-called “conformational diseases”, in which pro-
tein deposits are observed in specific tissues or cells. This is the
case for several neurodegenerative diseases such as Alzheimer or
Parkinson, among others.
Under a heat shock stress, about 150–200 different proteins
were identified as aggregation-prone in Escherichia coli (Winkler
et al., 2010). The formation of aggregates can be reversed by the
combined effect of chaperones and protease activities and the
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disaggregation machinery. As mentioned, aggregates are mainly
located at cellular poles by mechanisms not yet completely under-
stood. Recently Winkler et al. proposed that nucleoid occlusion is
the main driving force which determines the number and posi-
tioning of the protein aggregates in E. coli. Also, authors argued
against the idea that an active targeting mechanism was involved
in polar localization. Interestingly, polar localization allows an
asymmetric partitioning of protein aggregates between daughter
cells. This asymmetry allows an increased cell division rate in the
population devoid of aggregates, beneficial for the ageing of the
bacterial cell population (Winkler et al., 2010).
PREDICTION OF A PROTEIN’S AGGREGATION PROPENSITY
The aggregation behavior of a protein is strongly determined
by intrinsic properties of its amino acidic sequence. This obser-
vation supported the development of computational meth-
ods to predict protein aggregation propensity. Interestingly,
recent algorithms take into account not only the primary
sequence of the polypeptide, but also experimental proteome
data, including information about cellular localization, cytoso-
lic, periplasmic and membrane proteins. The analysis per-
formed by De Groot and Ventura (2010) using AGGRESCAN
-an algorithm developed by their group, (Conchillo-Sole et al.,
2007; De Groot et al., 2012)-, indicates that the aggre-
gation propensity of bacterial proteins is associated with
their length, conformation, location, function, and abundance.
Recently, in AMYLPRED2 11 predictive methods were consid-
ered, trying to produce a consensus prediction of amyloido-
genic determinants/“aggregation-prone” peptides in proteins,
from sequence alone (Tsolis et al., 2013) (http://biophysics.
biol.uoa.gr/AMYLPRED2). It is worth mentioning that other
factors affect the aggregation of recombinant protein expres-
sion in bacteria such as temperature and growth rate, fusion
to soluble protein tags, specific codon usage, tRNA availabil-
ity, and general optimization of codons in the heterologous
expressed sequence (Cortazzo et al., 2002; Rosano and Ceccarelli,
2009).
IBs STRUCTURE: A SPONGE-LIKE SUPRAMOLECULAR
ORGANIZATION
The formation and structure of IBs in E. coli expressing heterol-
ogous proteins has been extensively analyzed. Several excellent
reviews summarize the current knowledge on IBs structure and
formation (De Groot et al., 2008, 2009; Wang, 2009; Sabate et al.,
2010; Garcia-Fruitos et al., 2011, 2012). Here we present a concise
summary and extend a little more on the most recent published
data.
IBs are normally observed in the cytoplasm of the producing
bacteria as dense, large and apparently spherical or cylindrical
particle, ranging from 0.2 to 1.2μm, composed of 80–95% of the
heterologous expressed protein. IBs may also contain other pro-
teins, like small heat shock proteins (IbpA and IbpA) and chap-
erones (like the DnaK system), phospholipids from membranes
and nucleic acids and other background proteins that co-purify
with aggregates (Jurgen et al., 2010). Interestingly, the cellular
composition of IBs evolves during cell growth so that cellular pro-
teins are predominant during the first steps of formation, while
heterologous proteins become predominant at the end. These
changes occur in concert with the evolution of other parameters
inherent to cell growth, such as division time and growth rate,
leading to the idea that aging of bacterial population could be
related to protein aggregation (Lindner et al., 2008).
Different approaches have revealed that IBs bare a character-
istic cross-β structure, resembling that found in amyloid fibers
associated to a wide variety of human degenerative diseases.
Notwithstanding, IBs may also contain variable amounts of
natively folded proteins or partially folded proteins that can
acquire their native conformation even if they are embedded in
an aggregate (Gonzalez-Montalban et al., 2008). In fact aggre-
gates have been found to be composed of a wide spectrum of
conformations, ranging from native conformation to misfolded
aggregates (Schrodel et al., 2005; Rinas et al., 2007). Moreover,
aggregation and disaggregation have been shown to occur simul-
taneously in vivo in actively producing recombinant bacteria
(Carrio and Villaverde, 2002). The solubilized proteins can then
reach their native state or alternatively suffer partial proteolytic
degradation (Corchero et al., 1997; Carrio et al., 1999; Cubarsi
et al., 2001; Lethanh et al., 2005; Vera et al., 2005; Rinas et al.,
2007). The proportion of functional protein is characteristic of
the target protein’s sequence (Upadhyay et al., 2012), but also
depends on cell growth temperature (De Groot and Ventura,
2006; Peternel et al., 2008) and on the genetic traits of the host
strain (Garcia-Fruitos et al., 2009)
The cross-β sheet regions have been shown to be refractory
to proteinase K (PK) digestion, while native or native-like struc-
tures are highly sensitive to PK digestion. Using a GFP reporter
model, Cano-Garrido et al. (2013) have shown that when IBs are
submitted to mild digestion with the protease their morphology
or size is not affected while fluorescence emission and density
are notably diminished. They propose that IBs present a sponge-
like structure, where the PK resistant fibrils constitute a scaffold
which confers mechanical stability to IBs, while the functional,
PK sensitive fraction accumulate in the gaps of this scaffold.
In accordance to this, Walther et al. (2014) suggested a mecha-
nism of pore diffusion out of a barrier layer for the solubilization
of IBs. They propose that the solubilization process involves dif-
ferent layers in the IBs: a core, consisting of the IBs agglomerates,
a reactive and a diffusion layer. The densely packed inner cores
of protein shrink as the solubilized protein diffuses to the outer
layers and subsequently through a porous barrier layer into free
solution. The authors propose that this model correlates well with
the IBs structure suggested by Cano-Garrido et al. (2013), the bar-
rier layer corresponding to the amyloid scaffold, which becomes
visible only as solubilization progresses.
IBs A MODEL TO STUDY PROTEIN AGGREGATION RELATED
TO CONFORMATIONAL DISEASES
The formation and disaggregation of bacterial IBs gained growing
attention as models to study insoluble protein deposits observed
in some complex human diseases, as in the so-called “confor-
mational diseases”. This approach is strongly supported by the
concept that protein aggregation is part of a conserved cellular
response. Three examples have been chosen to illustrate how IBs
are employed as a model to study aggregation proteins involved
Frontiers in Microbiology | Microbiotechnology, Ecotoxicology and Bioremediation February 2014 | Volume 5 | Article 56 | 2
Ramón et al. Inclusion bodies: not that bad. . .
in particular human diseases and as a useful screening approach
for the search for aggregation inhibitors.
EXPANDED polyQ IN HUNTINGTON DISEASE
Huntington disease is a neurodegenerative disorder that affects
muscle coordination, followed by cognitive and psychiatric prob-
lems. The disease is caused by mutations in the Huntingtin gene,
in which expansion of the triplet CAG within the first exon of the
gene produces a protein carrying stretches of repeated glutamines
(polyQ). When polyQ exceeds a critical length, huntingtin pro-
tein undergoes amyloid aggregation (Orr and Zoghbi, 2007).
E. coli has been employed to follow in vivo the aggregation pro-
cess of an artificial protein harboring a polyglutamine (polyQ)
tract (Ignatova et al., 2007). E. coli growth rate was found to be
sensitive to the protein conformational state, and showed that
misfolded peptides and soluble aggregates were cytotoxic (Miller
et al., 2010).
Related to some pathologies, the relationship between “aggre-
gation” and “toxicity” is often controversial. This question was
recently explored in E. coli by expressing PolyQ-Containing
Ataxin-3 (Invernizzi et al., 2012). For this purpose, the toxicity
of three variants expressed in E. coli was determined according to
reduction of growth rate. The authors showed that toxicity was
correlated to the formation of soluble cytosolic oligomers, but
not to peptide aggregation. Instead, interestingly, the aggregates
appeared to be protective against cell toxicity (Invernizzi et al.,
2012).
PRION PROTEIN EXPRESSION IN BACTERIA
Prions are protein aggregates with self-perpetuating ability and
thus infectious (reviewed in Villar-Pique and Ventura, 2012).
Prions are involved in transmissible spongiform encephalopathies
(TSEs), a family of rare progressive neurodegenerative disorders
that affect both humans and animals. Bacterial IBs have been
exploited as a tool for the study of the structural and functional
characteristics of prions. Het-s, from the fungus Podospora anse-
rina, was the first prion protein whose bacterial IBs were shown
to display amyloid-like properties (Sabate et al., 2009; Wasmer
et al., 2009). These E. coli-produced aggregates were transfected
into prion-free fungal strains, and were shown to promote pri-
onic conversion of Het-s at levels comparable to those induced by
homologous amyloid fibrils (Sabate et al., 2009). A similar obser-
vation was reported in the case of the yeast prion Sup35. The IBs
of this protein were used to induce the [PSI+] prion in [psi-]
prion-free yeast strains. These results highlight the fact that the
infectivity rate can be easily modulated by tuning the environ-
mental conditions during the formation of IBs (Radchenko et al.,
2011; Sabate et al., 2012).
ALZHEIMER Aβ42 AGGREGATION
There is an increasing interest in developing methods to identify
cellular factors that trigger the aggregation of proteins inside the
organism as well as to discover drugs able to interfere with these
factors. Villar-Pique et al. (2012) describe a fast, cost-effective
high-throughput approach to study conditions and molecules
that affect Aβ42 aggregation. The assay is based on the use of
IBs formed by an Aβ42-GFP fusion protein in bacteria. They
showed the ability of the approach to detect the effect of metal
ions on Aβ42 aggregation as well as to identify compounds that
block metal-induced reaction. The authors further propose that,
as many proteins form IBs when expressed in bacteria (De Groot
et al., 2009), this approach may have a much larger applicabil-
ity in the search for aggregation modulators in conformational
disorders (Villar-Pique et al., 2012).
METHODS FOR THE RECOVERY OF FUNCTIONAL PROTEINS
FROM IBs
Considering IBs as a source of almost pure proteins, one possible
way is to attain the dissolution of aggregates in order to obtain
native-folded, active protein. The challenge is then to solubilize
and refold as much aggregated protein as possible and obtain a
stable, functional product. The cost of the whole process must
be taken into consideration if the aim is to produce a large-scale
manufactured product.
The rate and yield of the solubilization process seem to be
influenced by the conditions used, like chaotrope addition, con-
centration, temperature, pressure, etc. Even if there is no general
method to solubilize and refold a protein and the strategy in
each casemust be “custom-made”, most IBs protein-recovery pro-
cedures include the following steps (Burgess, 2009; Basu et al.,
2011): (i) overexpression of the selected protein in an appropri-
ate host strain; (ii) isolation of IBs; (iii) solubilization of IBs;
(iv) refolding (including disulfide bond formation when neces-
sary); (v) high-resolution chromatography (vi) quality control of
obtained material.
Solubilization and refolding are the most critical steps in
the procedure and successful conditions still depend mostly
on trial-and-error strategies (Burgess, 2009). Notwithstanding,
efforts have been made to rationalize the refolding step, the
free REFOLD database (http://refold.med.monash.edu.au;Chow
et al., 2006a,b) can be a useful tool for the design of procedures
for the refolding and purification of recombinant proteins.
There are very good recent reviews that compile the different
methods employed in the different steps of the recovery process.
In accordance to the above mentioned findings on the struc-
ture and solubilization mechanisms of IBs, the tendency is to
employ milder extraction conditions, avoiding strong denatura-
tion and refolding conditions. In Table 1we listed the most recent
approaches reported in the last 3 years.
IBs NANOPARTICULES AND CONTROLLED DELIVERY OF
DRUGS
A recent report showed that peptide hormones of the pituitary
gland are stored intracellularly as amyloid aggregates within the
secretion granules. The amyloid cross-β structure provides a very
stable and highly compacted state from which controlled release
of functional monomeric hormone can take place upon signal-
ing (Maji et al., 2009). A somewhat similar situation occurs with
bacterial IBs. In fact, IBs are composed by amyloid-like aggregates
from which substantial amounts of functional recombinant pro-
tein can be released in vivo as well as undermild (non-denaturing)
conditions in vitro. This feature—reminiscent of a drug delivery
system—led to the concept of the “nanopills,” i.e., nanoparti-
cles which are able to release proteins with therapeutic effects
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Table 1 | Novel approaches employed in the recovery of proteins from IBs.
Recovery step Strategy Advantage Protein References
Solubilization/Refolding 6M n-propanol Chaotropic effect at high
concentration/kosmotropic effect at
dilution helps refolding
r-hGH Singh et al., 2012




scFvs Kudou et al.,
2011a,b
Solubilization Non-reducing buffer + low concentration
of urea
Avoids inappropriate disulfide bonds
and aggregates. Suitable for proteins
that aggregate with native-like
structures
PrP Walsh et al., 2012
Solubilization Microwave assistance Shortens solubilization time various Datta et al., 2013
Refolding High hydrostatic pressure No previous protein denaturation
required
LECT2 Zheng et al., 2013
Refolding Dialysis against PE-PEG
(Polyethylene-Polyethyleneglycol)
Simple and cheap method; high yield FhuA 1-159 Dworeck et al.,
2011
Solubilization Alkaline-shock No use of chaotropic agents adiponectin Heiker et al., 2010
Refolding Solid-phase refolding in cation-exchange
resin with decreasing gradient of urea
Minimize time and number of steps BMP-2 dimers Rane et al., 2013
directly from the inside of cells (Vazquez et al., 2012). As a proof
of concept, Vazquez et al. demonstrated that the addition of dif-
ferent types of IBs to the culture medium of mammalian cells,
for example IBs composed of HSP70, leukemia inhibitory factor
or catalase, were able to rescue them from cis-platinum, serum
deprivation or oxidative stress, respectively. Also, dihydrofolate
reductase IBs complemented the intrinsic cell deficiency of this
enzyme. Furthermore, IBs are spontaneously internalized by cul-
tured cells, as was directly demonstrated with green fluorescent
protein IBs (Villaverde et al., 2012). Following a similar approach,
Liovic et al. (2012) introduced keratin 14 IBs into epithelial
cells which do not normally express this protein, and found that
intracellular keratin filaments start to form.
CONCLUDING REMARKS
The common view of IBs as undesirable by-products in recombi-
nant protein production have been lastly reconsidered, in view of
the potential of these structures for different purposes. On the
other hand, IBs provide to constitute an easy to handle model
for the study of the molecular basis of conformational diseases.
On the other hand, IBs provide a source of almost pure polypep-
tides and are a potentially useful source of ready-to-use protein.
In this sense, the aim is then to obtain IBs containing as much
folded, functional protein as possible. The design of strategies to
reach this aim requires a deep knowledge of IB’s structure and
formation, in order to identify possible molecular targets which
can be “tuned” to improve the protein recovery yield or to obtain
IBs with the desired characteristics to allow their use as enzyme
carriers or nanomaterials.
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